IP Library › Granted Patent US 8,124,732
Granted Patent B2
US 8,124,732 · App. 12/562,899 · Granted Feb 28, 2012

Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,124,732
App. No.
12/562,899
Granted
Feb 28, 2012
Kind
B2
Abstract

The invention encompasses among other things fusion proteins including Fc fusion proteins such as CTLA4-Fc having avian N-linked glycosylation patterns obtained from egg white of eggs laid by transgenic avians.

Claims (6)

1. A composition comprising isolated human cytotoxic T-lymphocyte-associated antigen 4 (CTLA4)-Fc fusion protein molecules wherein the CTLA4-Fc fusion protein molecules are produced in a transgenic chicken oviduct cell and are isolated from egg white of the transgenic chicken which contains a transgene encoding the CTLA-Fc fusion protein.

2. The composition of claim 1 wherein the oviduct cell is a tubular gland cell.

3. The composition of claim 1 wherein the CTLA4-Fc fusion protein is N-glycosylated.

4. The composition of claim 1 wherein the composition is a pharmaceutical composition.

5. The composition of claim 1 wherein the CTLA4-Fc fusion protein has the amino acid sequence set forth in SEQ ID NO:2.

6. The composition of claim 1 wherein the CTLA4-Fc fusion protein is contained in a hard shell egg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2009
From: HARVEY, ALEX J.
To: SYNAGEVA BIOPHARMA CORP.
Reel/Frame 023325/0590 →